-- 長春高新技術產業有限公司（深圳證券交易所代碼：000661）旗下子公司長春基因醫藥獲得中國監管機構批准，可生產和銷售其複心七白單株抗體注射。 根據週四提交給深圳證券交易所的文件，該藥物適用於對標準療法反應不佳的成人急性痛風性關節炎發作。
Related Articles
Asia
Humanwell Healthcare Gets Clinical Trial Approval for Opioid Alternative
Humanwell Healthcare (SHA:600079) unit obtained China's regulatory approval to begin clinical trials for RFUS-188 to treat acute pain, according to a Thursday filing with the Shanghai bourse.The drug targets peripheral kappa opioid receptors without crossing the blood-brain barrier, potentially eliminating the addiction, respiratory depression and other severe side effects of traditional opioidsShares of the pharmaceutical company declined 1% in recent trade.
$SHA:600079
Asia
Tibet Huayu Mining Shareholder to Divest 1% Stake in Company
A Tibet Huayu Mining (SHA:601020) shareholder plans to reduce part of its holdings to meet its own business development needs, according to a Shanghai bourse filing on Thursday.Qinghai Western Rare Precious Metals will offload 8,200,000 shares, or around 1% of the mining company's total shares, between May 29 and Aug. 28.Qinghai Western Rare Precious Metals currently owns 72,336,364 shares, or 8.8% of the company's total shares.
$SHA:601020
Asia
Taiwan Mask Mulls Private Placement of Up to 20 Million Shares; Shares Rally 10%
Taiwan Mask (TPE:2338) board approved a plan to privately place up to 20 million shares in one to three tranches within a year, according to a filing with the Taiwan Exchange on Wednesday.Shares of the photomask manufacturer jumped about 10% in Thursday's midday trade.Proceeds from the offering are earmarked for working capital, factory expansion, machinery and equipment procurement, debt repayment, and other long-term development needs.Potential subscribers may include insider and related parties such as Luminous Rise Investment, TrueLight Corp., Star Fusion Group, and ALi Corp. (TPE:3041), although no final placees have been selected, it said.
$TPE:2338